Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction

Show full item record




Levy , B , Clere-Jehl , R , Legras , A , Morichau-Beauchant , T , Leone , M , Frederique , G , Quenot , J-P , Kimmoun , A , Cariou , A , Lassus , J , Harjola , V-P , Meziani , F , Louis , G , Rossignol , P , Duarte , K , Girerd , N , Mebazaa , A & Vignon , P 2018 , ' Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction ' , Journal of the American College of Cardiology , vol. 72 , no. 2 , pp. 173-182 . https://doi.org/10.1016/j.jacc.2018.04.051

Title: Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction
Author: Levy, Bruno; Clere-Jehl, Raphael; Legras, Annick; Morichau-Beauchant, Tristan; Leone, Marc; Frederique, Ganster; Quenot, Jean-Pierre; Kimmoun, Antoine; Cariou, Alain; Lassus, Johan; Harjola, Veli-Pekka; Meziani, Ferhat; Louis, Guillaume; Rossignol, Patrick; Duarte, Kevin; Girerd, Nicolas; Mebazaa, Alexandre; Vignon, Philippe
Contributor organization: HUS Heart and Lung Center
Department of Medicine
Kardiologian yksikkö
University of Helsinki
HUS Emergency Medicine and Services
Date: 2018-07-10
Language: eng
Number of pages: 10
Belongs to series: Journal of the American College of Cardiology
ISSN: 0735-1097
DOI: https://doi.org/10.1016/j.jacc.2018.04.051
URI: http://hdl.handle.net/10138/304176
Abstract: BACKGROUND Vasopressor agents could have certain specific effects in patients with cardiogenic shock (CS) after myocardial infarction, which may influence outcome. Although norepinephrine and epinephrine are currently the most commonly used agents, no randomized trial has compared their effects, and intervention data are lacking. OBJECTIVES The goal of this paper was to compare in a prospective, double-blind, multicenter, randomized study, the efficacy and safety of epinephrine and norepinephrine in patients with CS after acute myocardial infarction. METHODS The primary efficacy outcome was cardiac index evolution, and the primary safety outcome was the occurrence of refractory CS. Refractory CS was defined as CS with sustained hypotension, end-organ hypoperfusion and hyperlactatemia, and high inotrope and vasopressor doses. RESULTS Fifty-seven patients were randomized into 2 study arms, epinephrine and norepinephrine. For the primary efficacy endpoint, cardiac index evolution was similar between the 2 groups (p = 0.43) from baseline (H0) to H72. For the main safety endpoint, the observed higher incidence of refractory shock in the epinephrine group (10 of 27 [37%] vs. norepinephrine 2 of 30 [7%]; p = 0.008) led to early termination of the study. Heart rate increased significantly with epinephrine from H2 to H24 while remaining unchanged with norepinephrine (p <0.0001). Several metabolic changes were unfavorable to epinephrine compared with norepinephrine, including an increase in cardiac double product (p = 0.0002) and lactic acidosis from H2 to H24 (p <0.0001). CONCLUSIONS In patients with CS secondary to acute myocardial infarction, the use of epinephrine compared with norepinephrine was associated with similar effects on arterial pressure and cardiac index and a higher incidence of refractory shock. (Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock [OptimaCC]; NCT01367743) (J AmColl Cardiol 2018; 72: 173-82) (C) 2018 by the American College of Cardiology Foundation.
Subject: acute myocardial infarction
cardiogenic shock
3121 General medicine, internal medicine and other clinical medicine
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0735109718347491_main.pdf 274.3Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record